Serpinb8 (CAP2): A novel Drug Target and Biomarker for the Treatment of Fibrosis and other Chronic Diseases

Target Name: SERPINB8

NCBI ID: G5271

SERPINB8

Serpinb8 (CAP2): A novel Drug Target and Biomarker for the Treatment of Fibrosis and other Chronic Diseases

Abstract:

Serpinb8 (CAP2) is a protein that is expressed in various tissues and cells throughout the body. Its functions include but are not limited to modulating the extracellular matrix (ECM), regulating the growth and differentiation of tissues, and playing a role in the development and progression of various diseases, including fibrosis. In this article, we will discuss the role of Serpinb8 (CAP2) as a drug target and biomarker, with a focus on its potential therapeutic applications in the treatment of fibrosis and other chronic diseases.

Introduction:

Fibrosis is a complex pathological process that involves the progressive accumulation of extracellular matrix (ECM) components, leading to the loss of tissue function and quality of life. Fibrosis can occur in various tissues, including but not limited to lungs, hearts, kidneys, livers, andAddress:

Protein Name: Serpin Family B Member 8

Functions: Has an important role in epithelial desmosome-mediated cell-cell adhesion

The "SERPINB8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SERPINB8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets